TSE:ASP Acerus Pharmaceuticals (ASP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acerus Pharmaceuticals Stock (TSE:ASP) 30 days 90 days 365 days Advanced Chart Remove Ads Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1,250 shsAverage Volume4,719 shsMarket CapitalizationC$2.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More… Remove Ads Receive ASP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASP Stock News HeadlinesAcerus UpdateMay 25, 2023 | benzinga.comClosing Bell: Acerus Pharmaceuticals Corp flat on Thursday (ASP)April 8, 2023 | theglobeandmail.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 5, 2025 | Paradigm Press (Ad)IIROC Trading Halt - ASPJanuary 26, 2023 | finance.yahoo.comAcerus Files For CCAA ProtectionJanuary 26, 2023 | finance.yahoo.comAcerus Announces New Loan Agreement With First Generation CapitalDecember 22, 2022 | finance.yahoo.comAcerus Pharmaceuticals Third Quarter 2022 Earnings: US$0.54 loss per share (vs US$0.64 loss in 3Q 2021)November 18, 2022 | finance.yahoo.comAcerus: Q3 Earnings SnapshotNovember 14, 2022 | sfgate.comSee More Headlines ASP Stock Analysis - Frequently Asked Questions How do I buy shares of Acerus Pharmaceuticals? Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Acerus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Absolute Software Co. (ABT.TO) (ABT), Achieve Life Sciences (ACHV) and Algonquin Power & Utilities (AQN). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:ASP CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($4.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,080,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-54.10% Debt Debt-to-Equity Ratio261.01 Current Ratio0.67 Quick Ratio0.26 Sales & Book Value Annual SalesC$3.04 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.29 Book ValueC($1.80) per share Price / BookN/AMiscellaneous Outstanding Shares7,710,000Free FloatN/AMarket CapC$2.78 million OptionableNot Optionable Beta1.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (TSE:ASP) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.